IL137811A - Vaccines containing interleukin-12 and the herpes simplex viral antigen - Google Patents

Vaccines containing interleukin-12 and the herpes simplex viral antigen

Info

Publication number
IL137811A
IL137811A IL13781199A IL13781199A IL137811A IL 137811 A IL137811 A IL 137811A IL 13781199 A IL13781199 A IL 13781199A IL 13781199 A IL13781199 A IL 13781199A IL 137811 A IL137811 A IL 137811A
Authority
IL
Israel
Prior art keywords
antigen
herpes simplex
interleukin
suspension
vaccine
Prior art date
Application number
IL13781199A
Other languages
English (en)
Hebrew (he)
Other versions
IL137811A0 (en
Original Assignee
Wyeth Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Wyeth Corp filed Critical Wyeth Corp
Publication of IL137811A0 publication Critical patent/IL137811A0/xx
Publication of IL137811A publication Critical patent/IL137811A/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/52—Cytokines; Lymphokines; Interferons
    • C07K14/54—Interleukins [IL]
    • C07K14/5434—IL-12
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A61K39/245—Herpetoviridae, e.g. herpes simplex virus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/39—Medicinal preparations containing antigens or antibodies characterised by the immunostimulating additives, e.g. chemical adjuvants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/20—Antivirals for DNA viruses
    • A61P31/22—Antivirals for DNA viruses for herpes viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55505—Inorganic adjuvants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511—Organic adjuvants
    • A61K2039/55522—Cytokines; Lymphokines; Interferons
    • A61K2039/55527—Interleukins
    • A61K2039/55538—IL-12
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011—Details
    • C12N2710/16011—Herpesviridae
    • C12N2710/16611—Simplexvirus, e.g. human herpesvirus 1, 2
    • C12N2710/16634—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Virology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Immunology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Organic Chemistry (AREA)
  • Microbiology (AREA)
  • Epidemiology (AREA)
  • Mycology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Molecular Biology (AREA)
  • Zoology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Communicable Diseases (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Engineering & Computer Science (AREA)
  • Toxicology (AREA)
  • Oncology (AREA)
  • Genetics & Genomics (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Biotechnology (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Peptides Or Proteins (AREA)
IL13781199A 1998-02-12 1999-02-10 Vaccines containing interleukin-12 and the herpes simplex viral antigen IL137811A (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US7450398P 1998-02-12 1998-02-12
PCT/US1999/002923 WO1999040938A2 (en) 1998-02-12 1999-02-10 Vaccines comprising interleukin-12 and herpes simplex viral antigen

Publications (2)

Publication Number Publication Date
IL137811A0 IL137811A0 (en) 2001-10-31
IL137811A true IL137811A (en) 2005-12-18

Family

ID=22119907

Family Applications (1)

Application Number Title Priority Date Filing Date
IL13781199A IL137811A (en) 1998-02-12 1999-02-10 Vaccines containing interleukin-12 and the herpes simplex viral antigen

Country Status (15)

Country Link
US (1) US6488936B1 (da)
EP (1) EP1053017B1 (da)
JP (1) JP2002502884A (da)
KR (1) KR100622716B1 (da)
CN (1) CN1224422C (da)
AT (1) ATE275421T1 (da)
AU (1) AU764036B2 (da)
BR (1) BR9907883A (da)
CA (1) CA2320041A1 (da)
DE (1) DE69919984T2 (da)
DK (1) DK1053017T3 (da)
ES (1) ES2226338T3 (da)
IL (1) IL137811A (da)
PT (1) PT1053017E (da)
WO (1) WO1999040938A2 (da)

Families Citing this family (20)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
HUP0201220A3 (en) 1999-05-13 2004-07-28 Wyeth Holdings Corp Madison Adjuvant combination formulations
EP1238086B1 (en) * 1999-12-17 2006-03-08 Wyeth Holdings Corporation Vaccine for enhancing immune responses to herpes simplex virus
US6977072B2 (en) 2000-10-27 2005-12-20 Irx Therapeutics, Inc. Vaccine immunotherapy for immune suppressed patients
US20070025958A1 (en) 2000-10-27 2007-02-01 Hadden John W Vaccine immunotherapy
KR100863368B1 (ko) * 2000-11-10 2008-10-13 와이어쓰 홀딩스 코포레이션 조합 보조 제제
US6867000B2 (en) 2000-12-07 2005-03-15 Wyeth Holdings Corporation Method of enhancing immune responses to herpes
JP2004099584A (ja) * 2002-05-02 2004-04-02 Keio Gijuku Ｈｓｖを用いた抗腫瘍剤
CN1301749C (zh) * 2005-12-09 2007-02-28 复旦大学 抗单纯疱疹病毒－2感染的多表位dna疫苗及其制备方法
US7790203B2 (en) * 2005-12-13 2010-09-07 Lowder Tom R Composition and regimen for the treatment of herpes simplex virus, herpes zoster, and herpes genitalia epidermal herpetic lesions
DK2068918T4 (da) 2006-09-26 2024-09-02 Access To Advanced Health Inst Vaccinesammensætning omfattende syntetisk adjuvant
US20090181078A1 (en) 2006-09-26 2009-07-16 Infectious Disease Research Institute Vaccine composition containing synthetic adjuvant
JP5797190B2 (ja) 2009-05-15 2015-10-21 アイ アール エックス セーラピューティクス， インコーポレイテッド ワクチン免疫療法
EP3124491B1 (en) 2009-06-05 2019-10-30 Infectious Disease Research Institute Synthetic glucopyranosyl lipid adjuvants and vaccine compositions as well as pharmaceutical compositions containing them
US8729058B2 (en) 2009-10-27 2014-05-20 Michael Zasloff Methods and compositions for treating and preventing viral infections
CN103097543A (zh) 2009-12-08 2013-05-08 伊尔克斯治疗有限公司 逆转朗格汉斯细胞免疫抑制的方法
JP6054942B2 (ja) 2011-04-08 2016-12-27 イミューン デザイン コーポレイション 免疫原性組成物、ならびに体液性および細胞性免疫応答を誘発するための該組成物の使用方法
CN107540730B (zh) 2012-05-16 2021-07-16 免疫设计公司 用于hsv-2的疫苗
BR112015025709A2 (pt) 2013-04-18 2017-07-18 Immune Design Corp monoterapia com gla para uso em tratamento de câncer
US9463198B2 (en) 2013-06-04 2016-10-11 Infectious Disease Research Institute Compositions and methods for reducing or preventing metastasis
EP3454878A4 (en) 2016-05-10 2020-07-29 Hennepin Healthcare Research Institute CYTOKINE IMMUNOMODULATORS AND SIGNALING METHODS

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1994022473A1 (en) * 1993-04-01 1994-10-13 University Of Washington Use of interleukin 7 to improve vaccine potency
US5571515A (en) * 1994-04-18 1996-11-05 The Wistar Institute Of Anatomy & Biology Compositions and methods for use of IL-12 as an adjuvant
IL114576A0 (en) * 1994-07-22 1995-11-27 Merck & Co Inc Polynucleotide herpes virus vaccine
GB9422990D0 (en) * 1994-11-15 1995-01-04 Cortecs Ltd Immunogenic compositions
WO1998008947A1 (en) * 1995-12-19 1998-03-05 The Government Of The United States Of America, Represented By The Secretary, Department Of Health And Human Services Enhancement of dna immunization through the use of cytokines

Also Published As

Publication number Publication date
ES2226338T3 (es) 2005-03-16
AU764036B2 (en) 2003-08-07
BR9907883A (pt) 2000-11-14
CN1224422C (zh) 2005-10-26
ATE275421T1 (de) 2004-09-15
DE69919984D1 (de) 2004-10-14
WO1999040938A2 (en) 1999-08-19
WO1999040938A3 (en) 2000-08-24
DE69919984T2 (de) 2005-11-17
US6488936B1 (en) 2002-12-03
AU2598199A (en) 1999-08-30
CN1299287A (zh) 2001-06-13
PT1053017E (pt) 2004-12-31
KR20010040867A (ko) 2001-05-15
EP1053017B1 (en) 2004-09-08
IL137811A0 (en) 2001-10-31
EP1053017A2 (en) 2000-11-22
KR100622716B1 (ko) 2006-09-13
CA2320041A1 (en) 1999-08-19
DK1053017T3 (da) 2004-11-22
JP2002502884A (ja) 2002-01-29

Similar Documents

Publication Publication Date Title
US6488936B1 (en) Immunogenic composition of interleukin-12 (IL-12), alum, herpes simplex viral (HSV) antigen, and method thereof
Morein et al. Current status and potential application of ISCOMs in veterinary medicine
Tighe et al. Conjugation of protein to immunostimulatory DNA results in a rapid, long‐lasting and potent induction of cell‐mediated and humoral immunity
Hu et al. Immunostimulating complexes (ISCOMs) for nasal vaccination
KR100278157B1 (ko) 보조약을 함유하는 백신 조성물
US5562910A (en) Vaccine compositions and method for enhancing an immune response
WO1998056415A1 (en) Purified saponins as oral adjuvants
CA2372960C (en) Hiv immunogenic compositions and methods
Bettahi et al. Protective immunity to genital herpes simplex virus type 1 and type 2 provided by self-adjuvanting lipopeptides that drive dendritic cell maturation and elicit a polarized Th1 immune response
Clarke et al. Mucosal priming of T-lymphocyte responses to fed protein antigens using cholera toxin as an adjuvant.
Dotsika et al. Influence of Quillaja saponaria triterpenoid content on the immunomodulatory capacity of Epstein–Barr virus Iscoms
Hassan et al. Immune responses in mice induced by HSV-1 glycoproteins presented with ISCOMs or NISV delivery systems
Yoo et al. Adjuvant activity of muramyl dipeptide derivatives to enhance immunogenicity of a hantavirus-inactivated vaccine
AU2005222909B2 (en) Enhanced activity of HIV vaccine using a second generation immunomodulatory oligonucleotide
Pertmer et al. Th1 genetic adjuvants modulate immune responses in neonates
Boyaka et al. Mucosal vaccines: an overview
Johansson et al. Iscoms with different quillaja saponin components differ in their immunomodulating activities
Papadopoulou et al. ISCOMs vaccine against experimental leishmaniasis
Tirabassi et al. A mucosal vaccination approach for herpes simplex virus type 2
Lacaille-Dubois Saponins as immunoadjuvants and immunostimulants
Yu et al. Synthetic innate defense regulator peptide combination using CpG ODN as a novel adjuvant induces long‑lasting and balanced immune responses
MXPA00007878A (da)
Morein et al. New ISCOMs meet unsettled vaccine demands
Sasaki et al. Live varicella vaccine polarizes the mucosal adjuvant action of cholera toxin or its B subunit on specific Th1‐type helper T cells with a single nasal coadministration in mice
KR20010040932A (ko) 인터루킨-12 및 호흡기 합포체 바이러스 항원을 포함하는백신

Legal Events

Date Code Title Description
FF Patent granted
KB Patent renewed
MM9K Patent not in force due to non-payment of renewal fees